Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regulating Cell Therapies: Conditional Approval Under Consideration In Congress; FDA Plans Public Hearing

This article was originally published in RPM Report

Executive Summary

Does FDA need a new pathway to consider advances in cellular therapy? Some in Congress think so. FDA is inviting stakeholders to weigh in this fall.

Advertisement

Related Content

Regenerative Medicine In Cures: Conditional Approval Dropped In Lieu Of ‘Breakthrough’-Style Approach
NIH Funding Component of 21st Century Cures May Get White House Boost

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register